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ABSTRACT African trypanosomes, except Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, which cause
human African trypanosomiasis, are lysed by the human serum protein apolipoprotein L1 (ApoL1). These two subspecies can
resist human ApoL1 because they express the serum resistance proteins T. b. gambiense glycoprotein (TgsGP) and serum
resistance-associated protein (SRA), respectively. Whereas in T. b. rhodesiense, SRA is necessary and sufficient to inhibit ApoL1,
in T. b. gambiense, TgsGP cannot protect against high ApoL1 uptake, so different additional mechanisms contribute to limit this
uptake. Here we report a complex interplay between trypanosomes and an ApoL1 variant, revealing important insights into in-
nate human immunity against these parasites. Using whole-genome sequencing, we characterized an atypical T. b. gambiense
infection in a patient in Ghana. We show that the infecting trypanosome has diverged from the classical T. b. gambiense strains
and lacks the TgsGP defense mechanism against human serum. By sequencing the ApoL1 gene of the patient and subsequent in
vitromutagenesis experiments, we demonstrate that a homozygous missense substitution (N264K) in the membrane-addressing
domain of this ApoL1 variant knocks down the trypanolytic activity, allowing the trypanosome to avoid ApoL1-mediated immu-
nity.
IMPORTANCE Most African trypanosomes are lysed by the ApoL1 protein in human serum. Only the subspecies Trypanosoma
b. gambiense and T. b. rhodesiense can resist lysis by ApoL1 because they express specific serum resistance proteins. We here
report a complex interplay between trypanosomes and an ApoL1 variant characterized by a homozygous missense substitution
(N264K) in the domain that we hypothesize interacts with the endolysosomal membranes of trypanosomes. The N264K substitu-
tion knocks down the lytic activity of ApoL1 against T. b. gambiense strains lacking the TgsGP defense mechanism and against
T. b. rhodesiense if N264K is accompanied by additional substitutions in the SRA-interacting domain. Our data suggest that
populations with high frequencies of the homozygous N264K ApoL1 variant may be at increased risk of contracting human Afri-
can trypanosomiasis.
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The human innate immunity is crucial to resist infection withAfrican trypanosomes. Only the subspecies Trypanosoma bru-
cei gambiense and Trypanosoma brucei rhodesiense can resist lysis
by most human sera and thus cause human African trypanosomi-
asis (HAT) in western/central and eastern/southern Africa, re-
spectively. T. b. gambiense has been historically divided into two
groups (1).T. b. gambiense group 1 (T. b. gambiense 1) is a homog-
enous group of isolates, constitutively resistant to human serum
and responsible for the majority of HAT cases. T. b. gambiense 2 is
a rather ambiguous group of strains which were isolated from
patients in the 1970s but do not form a monophyletic group (2)
and show varied levels of resistance to human serum (3).
T. b. gambiense 1 and T. b. rhodesiense are pathogenic to humans
because they developed resistance mechanisms against apolipo-
RESEARCH ARTICLE
crossmark
March/April 2016 Volume 7 Issue 2 e02198-15 ® mbio.asm.org 1
protein L1 (ApoL1), the trypanolytic component in human se-
rum (4).
ApoL1 is contained within two serum complexes, trypanolytic
factors 1 and 2 (TLF1 and -2) (5, 6). Both TLF1 and TLF2 are able
to lyse other trypanosomes, such asTrypanosoma brucei brucei and
Trypanosoma evansi, which cause nagana and surra in animals,
respectively, so these trypanosomes are not infectious to humans.
TLF1 can be efficiently taken up by trypanosomes through bind-
ing to the haptoglobin-hemoglobin (HpHb) receptor (6, 7).How-
ever, in normal human serum, the HpHb receptor is saturated
with serum HpHb, and ApoL1 enters the trypanosome only via
TLF2, independently of the HpHb receptor (6, 7). The exact
mechanism behind TLF2 uptake by trypanosomes is still un-
known. The trypanolytic activity of ApoL1 results from ionic pore
formation in endolysosomalmembranes, mediated by the combi-
nation of contiguous pore-forming and membrane-addressing
domains (8). T. b. gambiense 1 and T. b. rhodesiense resist ApoL1
through the activities of distinct resistance proteins. T. b. gam-
biense expresses the T. b. gambiense-specific glycoprotein
(TgsGP), which is necessary but not sufficient for full resistance,
and T. b. rhodesiense expresses the serum resistance-associated
protein (SRA) (9, 10). While TgsGP prevents ApoL1 pore-
forming activity by stiffening the target endolysosomal mem-
branes, SRA inhibits ApoL1 by direct interaction with the
C-terminal domain of this protein (4, 9, 11). The TgsGP gene is
physically linked to a truncation of a gene homologous to yeast
AUT1 (ATG3), a gene involved in internal vesicular formation
(12). T. b. gambiense is heterozygous for AUT1, with the full and
truncated alleles located in independent chromosome II homo-
logues (12). In hypohaptoglobinemic patients, receptor-mediated
uptake of TLF1 is efficient due to the absence of the competing
HpHb ligand for the HpHb receptor and can overcome the
TgsGP-mediated resistance of T. b. gambiense 1 (9). Therefore,
this parasite is characterized by an L210S substitution in the
HpHb receptor, which inhibits TLF1 uptake and allows T. b. gam-
biense 1 infection in regions with a high frequency of hypohapto-
globinemia (6, 9). Two variant ApoL1 alleles (G1 and G2) are
frequently observed in West Africans, presumably because these
variants resist inhibition by SRA and can thus lyseT. b. rhodesiense
(13). TheG1ApoL1 genotype is characterized by the coding single
nucleotide polymorphisms (SNPs) rs73885319 (S342G) and
rs60910145 (I384M) in the SRA-interacting domain, and the G2
ApoL1 genotype is characterized by the allele for indel rs71785313
(N388del and Y389del) in the same domain (13). None of 75
human sera with different combinations of G1 and G2 genotypes
were able to lyse T. b. gambiense in vitro, as was also observed with
recombinant G1 or G2 ApoL1 (13). Both TgsGP and SRA are
noncanonical variant surface glycoproteins (VSG), which are
routed to the lysosome of the trypanosome, in contrast to func-
tional native VSGs. Native VSGs cover the trypanosome plasma
membrane as a dense layer of homodimers and help to evade the
host’s immune system through continuous variation of surface-
exposed antigenic loops (14).
In this work, we report an ApoL1 variant in a patient in Ghana
whowas infectedwith an atypicalT. b. gambiense strain lacking the
TgsGP defense mechanism against ApoL1. The ApoL1 variant is
characterized by a homozygous N264Kmissense substitution that
knocks down its lytic activity against T. b. gambiense devoid of
TgsGP.
RESULTS
Patient. In 2013, a 54-year-old man presented at the Ghana Ports
and Harbours Authority Hospital in Takoradi City, Ghana, with
complaints of gastroenteritis, fever, and nausea. The patient was
HIV positive but not on antiretroviral therapy at the time of ad-
mission. He was taking co-trimoxazole as prophylaxis for HIV-
related opportunistic infections and artemisinin-based combina-
tion therapy against malaria. His hemoglobin level was 9.2 g/dl,
white blood cell count was 9.3 109/liter (58% neutrophils, 42%
lymphocytes), and platelet level was 259  109/liter. Giemsa-
stained thin blood smears revealed an infection with trypano-
somes, and he was treated with 10 injections of pentamidine at
4 mg/kg of body weight/day intramuscularly for 7 days. No lum-
bar puncture was performed. He responded well to the trypano-
cidal treatment, and no trypanosomes were microscopically ob-
served in blood films prepared after treatment. These blood films
did show the presence of malaria parasites. Because no HAT cases
have been reported in Ghana in the last 10 years, the blood of the
patient before treatment was collected on Whatman filter paper
for further analysis. Ethical clearance for the study was obtained
from the institutional ethics committee of the Institute of Tropical
Medicine, Antwerp, Belgium.
Trypanosome genome sequencing and SNP analysis.We ex-
tracted the DNA from the dried blood spot, and subsequent
whole-genome sequencing generated 10,738,766 paired-end
reads of 600 nucleotides (2  300 bp). Most (79.29%) of these
reads mapped to the human genome and were discarded. Many
(1,509,189) of the remaining reads could be mapped to the
T. b. brucei TREU927 reference genome, with 10-fold average and
7-fold median coverage. Sixty-two percent of the sample genome
(here referred to as the GHANA genome) with a minimum cov-
erage of 5 was used for SNP calling. Quality-scored reads have
been submitted to the NCBI Sequence Read Archive (accession
number SRP072325). Following mapping of all sequence data,
including publically available sequence data from T. b. gambiense
types 1 and 2, T. evansi, and T. b. brucei, SAMtools mpileup iden-
tified 78,899 SNPs. A RAxML maximum-likelihood tree revealed
a single monophyletic clade of T. b. gambiense 1 strains [DAL972,
1829(Aljo), and Fontem strain 10] (Fig. 1). The GHANA trypano-
some was genetically more related to T. b. gambiense 1 than to any
other trypanosome in this data set. The GHANA genome differed
from the T. b. gambiense 1 strains Fontem strain 10, DAL972, and
1829(Alijo) by, respectively, 7,950, 8,233, and 8,050 SNPs and
from the T. b. gambiense 2 strains TH126 and STIB386 by, respec-
tively, 15,050 and 15,437 SNPs. To exclude the possibility that the
GHANA trypanosome originated by recombination of T. b. gam-
biense 1 with another, related trypanosome, a NeighborNet Split
network was generated (Fig. S1). Reticulation was limited to the
center of the network, and no ambiguous phylogenetic signal re-
lated to T. b. gambiense 1 and GHANA was observed. In addition,
the GHANA sample showed the least number of heterozygous
SNPs compared to the other trypanosomes (see Table S2 in the
supplemental material). These results suggest that the GHANA
trypanosome is not a product of recombination. The gene for the
T. b. gambiense 1 serum resistance TgsGP protein was completely
absent from the GHANA genome. The absence of this gene was
further confirmed by PCR analysis with TgsGP-internal primers
(Fig. S2). Since the TgsGP gene is physically linked to a heterozy-
gous truncated AUT1 allele, we have tested the GHANA DNA by
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PCR with a primer set that amplifies the full AUT1 allele and a
primer set that amplifies the truncated AUT1 allele (Fig. S3).
GHANA showed a homozygous intact AUT1 gene, as in T. b. bru-
cei. However, the GHANA genome reads that mapped to the ref-
erence sequence of the HpHb receptor gene harbored the
T. b. gambiense 1-specific codon that is responsible for the L210S
substitution in theHpHb receptor. Because only one readmapped
to this region, we further confirmed this substitution by Sanger
sequencing of the complete GHANA HpHb receptor gene.
GHANA has the z1/z1 alleles of the T. b. gambiense 1 DAL972
strain (Fig. S4A) described by Symula et al. (15) and has the codon
for the L210S substitution in the HpHb receptor (Fig. S4B). This
L210S substitution in the HpHb receptor decreases the binding
and internalization of TLF1 in hypohaptoglobinemic-patient se-
rum (9). Given that our patient was anemic and coinfected with
malaria, the reduced uptake of TLF1 via the trypanosome’s mu-
tated HpHb receptor partially explains the resistance of the try-
panosome to human serum. However, it is known that ApoL1
can still enter the trypanosome via TLF2 and lyse trypanosomes
that do not have the TgsGP or SRA resistance proteins against
ApoL1 (9).
ApoL1 genotyping and in vitro mutagenesis experiments.
Sanger sequencing of exons 3 to 7 of the ApoL1 gene in the pa-
tient’s genome revealed a G2 ApoL1 genotype with homozygous
rs143830837 alleles (N388del andY389del) in the SRA-interacting
domain of ApoL1 (Fig. 2). The ApoL1 gene showed additional
substitutions in the pore-forming domain, rs2239785 G/A
(E150K) and rs136174 C/A (M228I), and in the membrane-
addressing domain, rs136176 G/A (R255K) and rs73885316 C/A
(N264K) (Fig. 2). The E150K, M228I, and R255K variants are
actually present in the ApoL1 wild-type (WT) version used in our
laboratory since the discovery of the trypanolytic potential of
ApoL1 (4), and these variants do not affect ApoL1 activity. M228I
and R255K are coded by the ApoL1 G3 genotype (16), and the
trypanolytic activity of ApoL1 G3 was confirmed using plasma
samples (17). Since previous experiments have indicated thatmu-
tations in themembrane-addressing domain can be deleterious to
trypanolytic activity (8), we decided to check the activity of the
N264K variant. Therefore, we experimentally introduced the
N264K substitution in WT, G1, and G2 ApoL1s by site-directed
mutagenesis and expressed these ApoL1 variants as recombinant
proteins (Fig. S5). The N264K variants of WT, G1, and G2 ApoL1
variants knocked down the lytic activity against T. b. gambiense 1
TgsGP knockout (KO) parasites (Fig. 3). Our mutagenesis exper-
iments also showed that the lytic activity of G1 ApoL1 against
serum-resistant T. b. rhodesiense was completely destroyed by the
N264K substitution. The same trend was observed with T. b. bru-
cei ribSRA. This is aT. b. brucei strain inwhich SRAwas genetically
introduced and which thus ectopically expresses SRA (10).
DISCUSSION
We successfully sequenced the genome of a trypanosome in a
dried blood spot from a HAT patient in Ghana. Using SNP and
targeted gene analysis, we showed that the trypanosome is an atyp-
ical T. b. gambiense strain that lacks TgsGP for its defense against
trypanolytic ApoL1 in human serum but has the T. b. gambiense
1-specific L210S substitution in its HpHb receptor. Given that the
patient was anemic, reduced uptake of TLF1 by the trypanosome
due to the mutated HpHb receptor may partially explain the re-
sistance to human serum. However, ApoL1 can still enter the try-
panosome via TLF2 and lyse trypanosomes that do not have the
TgsGP serum resistance protein. We have shown that the N264K
substitution in the membrane-addressing domain of the ApoL1
protein of the patient knocks down the trypanolytic activity
against this atypical T. b. gambiense strain devoid of TgsGP. Inter-
estingly, the intactAUT1 gene inGHANA indicates that this strain
has never harbored the TgsGP gene and that GHANA diverged
from the common ancestor before the T. b. gambiense type 1
strains. Because GHANA had the mutation for the L210S substi-
tution in its HpHb receptor, this also indicates that the T. b. gam-
biense-specific HpHb mutation existed before TgsGP was intro-
FIG 1 SNP analysis of the trypanosome in the patient and reference strains.
Shown is a bootstrapped RAxML maximum-likelihood tree based on 78,899
SNP loci identified in the patient’s trypanosome (GHANA) and on publically
available sequence data from three T. b. gambiense 1 strains, two T. b. gam-
biense 2 strains, five T. evansi strains, seven West African T. b. brucei strains,
and the East African T. b. brucei reference strain TREU927. Bootstrap values
were calculated on the basis of 1,000 replicates and are presented in the figure
if they were below 100%.
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FIG 2 (A)Nucleotide alignment of ApoL1 exon 7 of the patient (alleles 1 and 2) and the wild-type ApoL1 gene (ref; GenBank accession numberNM_003661.3);
(B) amino acid alignment of WT ApoL1 and ApoL1 of the patient (GHANA). Allele variants in panel A are indicated with the dbSNP codes, and Sanger
(Continued)
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duced and before the monophyletic human pathogen T. b.
gambiense type 1 emerged.
ApoL1 is targeted to membranes by its membrane-addressing
domain (8). After ApoL1 is inserted into the lysosomal mem-
brane, its pore-forming domain createsmembrane pores that lead
to trypanosome death (18). The N264K substitution in the
membrane-addressing domain of G2 ApoL1 of the patient thus
explains why he was infected with the atypical T. b. gambiense
strain devoid of TgsGP. In contrast, G2 ApoL1 N264K still effi-
ciently lysed T. b. brucei, T. evansi, and T. b. rhodesiense. When we
introduced the N264K substitution in G1 andG2ApoL1 proteins,
both variants could lyseT. b. brucei andT. evansi. The observation
that N264K affects only the lytic activity of ApoL1 against
T. b. gambiense devoid of TgsGP and not T. b. brucei and T. evansi
is probably due to the lower inherent sensitivity of the T. b. gam-
biense TgsGP KO to ApoL1, caused by a decreased ApoL1 uptake
Figure Legend Continued
sequencing chromatograms are included for alleles rs73885316 C/A and rs14380837. The green, blue, and purple sequences in panel B represent, respectively, the
pore-forming domain, the membrane-addressing domain, and the SRA-interacting domain of ApoL1 (8). Underlined sequences represent alpha helixes. These
helices are defined in reference 8; in the pore-forming domain, they were defined by homology modeling using the pore-forming domain of colicin A as the
template. Amino acid substitutions or deletions, as well as the amino acid positions, are indicated in red.
FIG 3 Trypanolytic activities of WT, G1, and G2 ApoL1s and the N264K variants. Shown is the growth of T. b. brucei, T. b. brucei ectopically expressing SRA
(ribSRA), human-serum-resistant (R) and sensitive (S) clones of T. b. rhodesiense, T. b. gambiense 1, the T. b. gambiense 1 TgsGP knockout (KO), and T. evansi
in complete growthmedium supplemented with various concentrations of recombinantWTApoL1 (A), ApoL1G1 (B), and ApoL1G2 (C), as well as the N264K
variants ApoL1 N264K (D), ApoL1 G1 N264K (E), and ApoL1 G2 N264K (F). Histograms for the 7 strains in the presence of 10 g/ml recombinant ApoL1
protein are shown for each ApoL1 variant. The physiological concentration of ApoL1 in human blood is approximately 10 g/ml. Completely lysed trypano-
somes in the histograms are indicated by “u.d.l.” (under the detection limit).
Trypanosome-ApoL1 Interaction
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in hypohaptoglobinemic serum and an accelerated degradation of
the internalized ApoL1 (9). Interestingly, the N264K substitution
also completely knocked down the lytic activity of G1 ApoL1
against T. b. rhodesiense, although N264K is located in the
membrane-addressing domain of ApoL1 and not in the domain
that binds to the T. b. rhodesiense resistance protein SRA. How-
ever, theN264KG2ApoL1 could still lyseT. b. rhodesiense. G1 and
G2 ApoL1 proteins have different mutations in the SRA-binding
domain ablating the serum resistance of T. b. rhodesiense, the G1
variant being weaker than the G2 variant in lysing T. b. rhod-
esiense, presumably due to higher residual binding to SRA (13).
Therefore, the higher susceptibility to N264K knockdown for the
G1 variant inT. b. rhodesiensemay result from the increased prob-
ability of interactionwith SRA following a lowered ability to access
the target membrane.
The G2 ApoL1 gene of the patient was characterized by a ho-
mozygote missense mutation (rs73885316 C/A) causing an
N264K substitution in the membrane-addressing domain of
ApoL1 and a homozygote 6-bp deletion (rs143830837) causing
theN388del andY389del deletions in the SRA-interacting domain
of ApoL1. According to the 1000 Genomes Project, 31 individuals
were heterozygous for the rs73885316 C/A allele, of which 8 indi-
viduals were heterozygous for the rs143830837 deletion; none
were homozygous for rs73885316 C/A or rs143830837. This sug-
gests that bothmutations probably arose independently on differ-
ent haplotypic backgrounds, given that they are only 368 bp apart.
Therefore, the observation that the patient is homozygous for
both rs73885316 (N264K) and rs143830837 (N388del and
Y389del) is remarkable, as it could have happened only through
convergent evolution (allowing the same mutations to arise in
different haplotypes) or through recombination (allowing the
mutations to bemerged on the same haplotype). Ko et al. reported
that the allele for the N264K ApoL1 variant is frequently observed
(34%) in the Hadza population in Tanzania (16). Following the
Hardy-Weinberg equilibrium, we expect 11.5% homozygous
N264K ApoL1 variants in the Hadza population. Given that the
Hadza live in an area where T. b. rhodesiense is endemic, our data
thus suggest that about 11% of the people may be at increased risk
of contracting HAT, since the N264K substitution knocks down
the protective effect of G1 ApoL1 against T. b. rhodesiense. The G1
genotype is characterized by an S342G (rs73885319) and an
I384M (rs71785313) substitution in the SRA-interacting domain
of ApoL1, and both alleles are present in the Hadza population
with a 5% frequency (16).
In conclusion, we report that themissense N264K substitution
in the membrane-addressing domain of WT, G1, and G2 ApoL1s
knocks down the lytic activity against T. b. gambiense strains de-
void of the TgsGP serum resistance mechanism. Interestingly, the
N264K substitution also knocks down the lytic activity of G1
ApoL1 against T. b. rhodesiense. Trypanosomes are ancient para-
sites that have existed together with human populations on the
African continent through evolution. Our findings illustrate the
sensitive interplay between ApoL1 genotypes and susceptibility to
trypanosome infection (19).
MATERIALS AND METHODS
Ethics. Ethical clearance for the study was obtained from the Institutional
Review Board (IRB) of the Institute of Tropical Medicine, Antwerp, Bel-
gium (approval number IRB/AB/ac/108). No informed consent of the
study participant could be given because the patient died before the results
of the molecular laboratory tests were available. The IRB gave approval to
publish our findings without informed consent, as the patient is anony-
mized in the report.
Genome sequencing and SNP analysis. DNA from three 5-mm
punches of dried blood of the patient was extracted from the filter paper
using the QIAamp DNA microkit according to the manufacturer’s in-
structions (Qiagen, Germany). One nanogram of genomic DNAwas sub-
jected to Illumina’s Nextera XT library preparation, and the library was
quantified with the KAPA library quantification kit (KAPA Biosystems,
MA). The indexed library was sequenced at a final concentration of 33 pM
in a MiSeq sequencer using a reagent v3 600-cycle cartridge (Illumina,
CA). With Bowtie 2 under default settings (20), we first discarded the
GHANA reads that mapped to human genome version 19 and then
mapped the reads of GHANA and the publically available genome reads
from the T. b. gambiense 1 strains DAL972 (21), Fontem strain 10, and
1829(Aljo) (22), the T. b. gambiense 2 strains TH126 and STIB386 (21),
the T. evansi strains STIB810, E110, C13, KETRI2479, and STIB805 (23),
and the West African T. b. brucei strains TSW187/78E, LM56clone6,
TSW55, KP33clone16, PTAG129, B8/18cloneB, and SW3/87 (22) to the
T. b. bruceiTREU927 reference genome (24). The list of strainswith coun-
try, host, and date of collection is presented in the supplemental material
(see Table S1). Variants were called with SAMtools’ mpileup function and
bcftools (25). The resulting vcf file was filtered to retain only SNPs with
read depths of5 in all strains, an SNP quality of50, a mapping quality
of 40, and no significant strand bias (P  0.05). For each strain, SNPs
were concatenated to a FASTA sequence in which each SNP was repre-
sented as 2 bases, one for each allele, and invariant sites were subsequently
removed. RAxML v8.1.17 was used to construct a maximum-likelihood
tree with 1,000 bootstraps using a GTR CAT substitution model and the
Felsenstein correction for ascertainment bias inherent to SNP alignments
(26). To check for possible recombination events, a NeighborNet Split
network of the SNP alignment was generated in Splitstree4 (27). The
presence and sequence of the HpHb receptor, TgsGP, and SRA genes in
the genomes was checked by mapping the sequencing reads against the
FASTA sequences of these genes (NCBI accession number JX143837 for
the HpHb receptor gene, FN555988 for TgsGP, and Z37159 for SRA)
using Bowtie2 and by visual inspection with the Integrated Genomics
Viewer (IGV) (28).
TgsGP and HpHb receptor analysis. The presence of the TgsGP
gene in GHANA was verified by PCR amplification with TgsGP internal
primers reported by Radwanska et al. (29). The presence of a truncated
AUT1 allele was verified as described by Felu et al. (12) but with the
primers AUT1-Fwd (5= GTTGAGGATGAACAAACAAAGTTTGTATG
AAGG 3=), AUT1-Full-Rev (5=CATTTTTAAATGTCGATACCTGTCGA
CAAATCATATTCG 3=), and AUT1-Trunc-Rev (5= ATATTCGTATATA
CACTCTCACAACACTCTCATATCATTATTATTATC 3=). The HpHb
receptor gene was PCR amplified and Sanger sequenced as described else-
where (9, 15). Successful DNA extraction from the dried blood on filter
paper was verified by amplifying a part of the trypanosome’s 18S rRNA
gene and the patient’s cytochrome b gene with primers described previ-
ously (30, 31).
ApoL1 genotyping and mutagenesis. To characterize the patient’s
ApoL1 protein, exons 3 to 7 of this gene were amplified using PCR as
described previously (32). ApoL1 PCR products were cloned in pCR-
Blunt vectors, and six to eight clones per exon were Sanger sequenced.
Amino acid sequences of the exons were aligned against the ApoL1 refer-
ence sequence (NM_003661.3, NCBI). ApoL1 G1, ApoL1 G2, and the
N264K variants were obtained by site-directedmutagenesis ofWTApoL1
cloned in the pStaby expression vector (Delphi Genetics). Recombinant
ApoL1 variantswere expressed inEscherichia coli in fusionwith theHis tag
and affinity purified on nickel columns (11). Trypanosome strains used in
the lysis experiment were T. b. gambiense 1 ELIANE (clone LiTat1.3),
T. b. gambiense 1 TgsGP KO, T. b. brucei Lister 427, T. b. brucei ribSRA,
T. b. rhodesiense Etat1.2 R (serum-resistant phenotype) and S (serum-
sensitive phenotype), and T. evansi RoTat 1.2. The transgenic cell lines T.
Cuypers et al.
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b. gambiense 1TgsGPKOandT. b. brucei ribSRAwere described earlier (9,
10). Bloodstream forms were diluted at 1  105 trypanosomes/ml
(T. b. brucei andT. b. rhodesiense) or 2 105 trypanosomes/ml (T. b. gam-
biense 1 and T. evansi) in HMI (Hirumi Modified Escove [33]) medium
containing 10% fetal calf serum (FCS) and 10% Serum Plus. Appropriate
dilutions of the recombinant proteinsweremade in 20mMacetic acid and
added to the trypanosomes as 10% of the final volume. Lysis tests were
performed in triplicate, and parasites were incubated overnight under
standard culture conditions. Quantification was performed with the Cell-
Titer Glo luminescence assay (Promega), and control growth conditions
with addition of only acetic acid were used as the reference (100%
growth).
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